NCT06424444View on ClinicalTrials.gov

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

421

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

November 3, 2024

Study Completion Date

November 3, 2024

Conditions
Dry Eye Disease
Interventions
DRUG

Reproxalap ophthalmic solution (0.25%)

Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks

DRUG

Vehicle ophthalmic solution

Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks

Trial Locations (1)

28150

Core, Inc., Shelby

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY